Earnings Leaders Portfolio Series 4 (FSMFOX)

Wh wait to pick up shares from sellers….there are plenty of shares…..insiders can buy at will…

Because he has Zero Shares of RKT...

Well, maybe this new tune of mine will cheer you all up a bit...have a listen! https://www.youtube.com/watch?v=V97AlWeOkeU&list=RDV97AlWeOkeU&start_radio=1

I was waiting for Sn Antonio to blow it again. Game 4 is crucial to each team. Knicks win, it's probably over. San Antonio wins, it's a brand new series, best 2 out of 3. Brunson is unbelievable in 4th quarters. James Hardin needs lessons from him.

Pancreatic cancer. Standard of care: 8.5 months.
$IMRX
drug: 17.3 months. Doubled survival. Zero drug-related toxicity.
Down 20% this month. Pipeline priced at $82M.

I'm trying to decide if Mnuchin or Bessent was more entertaining with Max on the attack. Bessent definitely got the better of her "....can someone get him to shut up...." but Mnuchin was completely dominated by her unwillingness to dismiss him to go to another engagement...we need more Max on camera

Smart investors should do their own d/d & not listen to the PAID BASHERS & NAKED SHORT SELLERS. It's obvious they have an agenda against the company & trying to cover up a MASSIVE SHORT position. Who else bashes a company with a bunch of LIES for decades & then claim to have no interests in the comp

Oh, I see. Okay, well, must've been awfully snarly too tho eh ?
Or not.....Admin CAN be arbitrarily rather fickle.

Sheesh lookit URG here huh - Right back to 1.65 ? 'At's about a 24% decline

https://investorshub.advfn.com/uimage/uploads/2026/6/8/tucnhurg_june_2_8

Are you saying you were a Photonics Engnieer working with photonics at Intel for 35 years?

Can you expound on your experience please?

Actually READ FDA ECA Guidelines:

"Sponsors should finalize a study protocol before initiating the externally controlled trial, including selection of the external control arm and analytic approach, rather than selecting an external control arm after the completion of a single-arm tri

Elephant in the room. After the "blah blah...blah" is over the speeding wheels of the bureaucracy will make this a many months process during which any number of events could derail it. Unfortunately the next president probably won't even discuss these things.

Remember the USS Liberty:

Attacked by israel:

https://www.youtube.com/watch?v=OqmoiUO4UDo

Z

Remember the USS Liberty:

Attacked by israel:

https://www.youtube.com/watch?v=OqmoiUO4UDo

Z

If a person doesn't like a stock, that's fine, then move on.
Why keep posting and show your immaturity? Who are they trying to impress?

The stock goes down every day..
More and more.
And the 47. Rates go down every
Day .
He must do it NOW!!!
Not bla bla bla...

Dr. Kalinski is the sponsor, NWBO is one of the collaborators.

Are you really letting a keyboard warrior getting under your skin, come on buddy! There is nothing anybody says on this sht show forum that means 2 fks to anyone. Don’t let this hub get to you bro. This whole hub is a sht show

Al-Than's bloated resume'--- Prior to his current role (with Ameerex), he served as the Assistant CEO of Qatar General Group (a major Qatari insurance and investment conglomerate) from 2015 until 2020, where he honed his expertise in managing massive multi-billion-Riyal investment portfolios . Yeah

"It is being 'shorted' so *Insiders* can 'scoop up' the Cheap shares OR are you saying we could expect these shares will be given to "WamU Escrow-holders for our Assets? "

NEITHER. The theory goes that there's apparently 100's of Millions of Class-L shares that are going to be convert

https://x.com/PikachOTC/status/2062848269726728334

ENZC

The stock price after submittal says it all. Little to no one cares about this anymore in my opinion.

I do have trading shares in Ira.though.never sold in other acct.

We've been trading in a channel the past three months. And we traded within that channel today. I was hoping the latest news would push us past $.01.

News of returning shares to the Treasury would do it, I bet.

The flaw in your argument is a class/category error.

You are applying a tissue-agnostic biomarker framework developed for a specific new class of oncology drugs — molecularly targeted therapies — to a different new class of treatment: dendritic-cell immunotherapy.

Those